TABLE 1.
Susceptibility to selected quinolones and fluoroquinolones of S. suis strains
| Strain | MIC (μg/ml)a
|
Country or region | Source or reference | |||||
|---|---|---|---|---|---|---|---|---|
| CIP | CIP+R | ENR | NOR | LVX | NAL | |||
| ATCC 43765 | 0.5 | 0.5 | 0.5 | 4 | 1 | >64 | England | Collection |
| BB1001 | 0.5 | 0.5 | 0.5 | 2 | 1 | >64 | Spain | This study |
| BB1002 | 0.5 | 0.5 | 0.5 | 2 | 1 | >64 | South America | This study |
| BB1003 | 0.5 | 0.5 | 0.5 | 4 | 0.5 | >64 | Spain | This study |
| BB1004 | 0.5 | 0.5 | 0.5 | 2 | 1 | >64 | Spain | This study |
| BB1005 | 0.5 | 0.5 | 0.25 | 4 | 0.5 | >64 | Spain | This study |
| BB1006 | 2 | 1 | 1 | 32 | 1 | >64 | Spain | This study |
| BB1007 | 8 | 4 | 4 | 16 | 4/2 | >64 | Spain | This study |
| BB1008 | 64 | 32 | 32 | >64 | 16 | >64 | Spain | This study |
| BB1009 | 32 | 16 | 16 | 32 | 16 | >64 | Spain | This study |
| BB1010 | 32 | 16 | 32 | >64 | 32 | >64 | Spain | This study |
| BB1011 | 16 | 16 | 16 | 32 | 16 | >64 | Spain | This study |
| BB1012 | 32 | 16 | 8 | >64 | 16 | >64 | Spain | This study |
| BB1013 | 64 | 16 | 8 | >64 | 16 | >64 | Spain | This study |
| BB1014 | 64 | 16 | 16 | >64 | 32 | >64 | Spain | This study |
| BB1015 | 32 | 16 | 16 | >64 | 16 | >64 | Spain | This study |
| BB1016 | 32 | 16 | 8 | >64 | 32 | >64 | South America | This study |
| BB1017 | 64 | 16 | 16 | >64 | 64 | >64 | Spain | This study |
a
CIP, ciprofloxacin; ENR, enrofloxacin; LVX, levofloxacin; NAL, nalidixic acid; NOR, norfloxacin; R, reserpine (10 μg/ml).